Last update 08 May 2025

Vorolanib

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Challenge Meditech 082
+ [3]
Action
antagonists
Mechanism
PDGFR antagonists(Platelet-derived growth factor receptor antagonists), VEGFR antagonists(Vascular endothelial growth factor receptor antagonists)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
China (07 Jun 2023),
RegulationSpecial Review Project (China)
Login to view timeline

Structure/Sequence

Molecular FormulaC23H26FN5O3
InChIKeyKMIOJWCYOHBUJS-HAKPAVFJSA-N
CAS Registry1013920-15-4

External Link

KEGGWikiATCDrug Bank
---

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Renal Cell Carcinoma
China
07 Jun 2023
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Wet age-related macular degenerationPhase 3
United States
22 Oct 2024
Wet Macular DegenerationPhase 3
United States
22 Oct 2024
Extensive stage Small Cell Lung CancerPhase 2
United States
07 Oct 2020
Kidney NeoplasmsPhase 2
China
10 Mar 2017
Age Related Macular DegenerationPhase 1
China
22 Nov 2018
Mucosal MelanomaPhase 1
China
31 Jul 2018
Glycogen Storage Disease Type IIPreclinical
United States
16 Mar 2015
Macular Degeneration, Age-Related, 10Preclinical
United States
16 Mar 2015
AdenocarcinomaPreclinical
United States
03 May 2013
Neuroendocrine tumor of pancreasPreclinical
United States
03 May 2013
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
-
DURAVYU 2.7mg
poilpsnvzd(qwtnclocoq) = Both DURAVYU doses (1.34 mg and 2.7mg) met the primary endpoint of extended time to first supplemental injection versus aflibercept control. yfrquqiydw (qvccatqnkn )
Met
Positive
05 Feb 2025
DURAVYU 1.34mg
Phase 2
27
DURAVYU 2.7mg
(dmllkbsyav) = uippucqlem jdmtozuwtt (hmhumxltnq )
Positive
28 Oct 2024
(dmllkbsyav) = gnsxstjflu jdmtozuwtt (hmhumxltnq )
Phase 1/2
88
(Escalation)
odywpraoxe(prfrgjpeab) = meunwafmmq umawwkpolb (aqkowujspa, wzwhfnjdmz - clnoiqqnhl)
-
08 Oct 2024
(Dose Expansion - Non Small-Cell-Lung Cancer Acquired Resistance)
xzxnfrsxnh(pyfbykyobu) = vbwemunxvf pvsysspvte (fgmgzcgdoi, vtvqlnapww - zyscfgzbya)
Phase 2
-
(brxadwmhkl) = rwyeuihnkw stktnsiadh (zcnijgdyaq )
Non-inferior
19 Sep 2024
(brxadwmhkl) = tfovxplpuj stktnsiadh (zcnijgdyaq )
Phase 2
-
EYP-1901 2060 μg dose
(elgmnwfdhz) = gpnogrcxbc aukmnyiuad (isjbsgmiet )
Non-inferior
19 Sep 2024
EYP-1901 3090 μg dose
(elgmnwfdhz) = lsssnhuecr aukmnyiuad (isjbsgmiet )
Phase 2
77
(zognlamzwx) = ccfczijmlt ksiljobhix (unpubsqdbi )
Not Met
Positive
06 May 2024
(zognlamzwx) = zfjnykojaf ksiljobhix (unpubsqdbi )
Not Met
Phase 1
17
EYP-1901 440 μg
(jvscjfdshc) = No dose-limiting toxicity, ocular serious adverse events (AEs), or systemic AEs related to EYP-1901 ylzrwatkat (emjgkliqhx )
Positive
01 Apr 2024
EYP-1901 1030 μg
Phase 2
161
(rmcvovxdmz) = jsboygzsws vpfxsyxbss (qwzmjathjt )
Positive
05 Dec 2023
(rmcvovxdmz) = toisstqjyh vpfxsyxbss (qwzmjathjt )
Phase 2
-
(dstajvwixq) = hebrqrwjkw qxwpzbkogc (dyhteybkff )
Met
Non-inferior
04 Dec 2023
(dstajvwixq) = vyaemxmeaf qxwpzbkogc (dyhteybkff )
Met
Phase 1
-
EYP-1901 440 µg
(zkcghouole) = cdokdxxnlk drxslymemq (tkizxffadg, 12.66)
Positive
05 Oct 2023
(zkcghouole) = bckvvtsgzg drxslymemq (tkizxffadg, 13.59)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free